Advertisement


Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3

ASCO 2026

Advertisement

Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EMERALD-3 was an expected and looked-forward-to study because, for the first time, for the most commonly used therapy in liver cancer, which is chemoembolization, we're trying to see if we can empower it further by adding on immunotherapy. Why would you do that? Because, understandably, when you do the embolization, you release antigens, which really will be an opportunity for enhancing the activity of the immune checkpoints. And there's such an opportunity for us to apply checkpoint inhibitors like anti–PD-L1, which is durvalumab in our example. And added to this, it can be enhanced further by anti-VEGF, where our example was lenvatinib. And of course, most importantly, we're really covering all of that from the top of this chain of command, which is anti–CTLA-4, with tremelimumab. As far as the study was to look into tremelimumab plus durvalumab, which we call the STRIDE regimen, as you know, plus lenvatinib plus chemoembolization, or TACE, and arm B was STRIDE again plus TACE, and arm C was TACE. The primary endpoint was to look at STRIDE, lenvatinib, and TACE compared with TACE alone. But of course, we looked at everything else because PFS was the primary endpoint, but we took it to OS, reported PFS for arm B as well, etc. This study showed an impressive improvement in outcome in regard to the PFS for arm A versus arm C. And even though we were able to report the data on all 4 parts of the study, being PFS for A versus C, PFS for B versus C, OS for A versus C, and OS for B versus C, however, it was not formally analyzed because we're waiting for any hierarchical kind of order, waiting for the maturity of each one of those steps. And as such, the overall survival, which was critical, showed an improvement in outcome in favor of both the STRIDE, lenvatinib, and TACE and also in favor of the STRIDE plus TACE. We were intrigued, and I'm so happy and I'm so thankful for all colleagues who asked, like, what about A versus B, which was really good news. We preplanned it, and we did report that as well. We're now comparing STRIDE plus lenvatinib plus TACE versus STRIDE plus TACE. And we found out that really adding on or not adding on the lenvatinib did not matter much, ie, we can say that it stands here for us, probably, will be the STRIDE plus TACE. One caveat. Interestingly, for only the population who are from Japan and also for the nonviral, maybe it favored the lenvatinib addition added to the STRIDE plus TACE. Of course, more analysis would come and follow accordingly. Last point, in regard to adverse events, thankfully, we did not see anything of concern. The expected concerns that will bring in with embolization were there, specifically the postembolization syndrome, and add to this the classic standard that you can see some reporting of. But thankfully, nothing critically of grade 3 or 4 except for the hypertension, which was noted, of course, in the lenvatinib arm, arm A. I would say that, from the patient perspective, patient-reported outcomes are definitely valuable, and I think we'll definitely look forward to reporting all this information later. As you all know, if you didn't catch up on any of those details, the good news is it's already accepted and in press for The Lancet Oncology, and on behalf of all my colleagues, I'm delighted to report that information. And yes, everybody asked me, and this is very true. Tomorrow I'll be in clinic, and guess what standard-of-care therapy is going to be? STRIDE plus TACE.

Related Videos

Pancreatic Cancer

Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers

Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527). 

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Leukemia
Lymphoma

Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial

Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).

For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).

Gastroesophageal Cancer

Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX

Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).

Breast Cancer

Jana de Boniface, MD, PhD, on Breast Cancer With Sentinel Lymph Node Macrometastases: Can Axillary Dissection Be Omitted?

Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).

Advertisement

Advertisement




Advertisement